Advertisement

Targeting the Wnt Pathway in Cancer

  • Kathleen H. Goss
  • Michael Kahn

Table of contents

  1. Front Matter
    Pages i-xi
  2. Paul Polakis
    Pages 1-18
  3. Xiaofang Tang, Xiaolan Fan, Xinhua Lin
    Pages 19-33
  4. Philipp C. Manegold, Jia-Ling Teo, Michael Kahn
    Pages 35-50
  5. Michael Thompson, Kari Nejak-Bowen, Satdarshan P. S. Monga
    Pages 51-80
  6. Jenifer R. Prosperi, Hue H. Luu, Kathleen H. Goss
    Pages 81-128
  7. Markus Müschen
    Pages 129-142
  8. Aliaksei Holik, Alan R. Clarke
    Pages 165-182
  9. Ho-Jin Lee, Xinxin Zhang, Jie J. Zheng
    Pages 183-209
  10. Miki Shitashige, Tesshi Yamada
    Pages 211-225
  11. Back Matter
    Pages 227-240

About this book

Introduction

The Wnt pathway is an evolutionarily conserved signaling network that is critical for mammalian development and adult tissue maintenance, and, importantly, hyperactivated in most human cancers. Almost two decades of study has confirmed that Wnt signaling is necessary and sufficient for cancer pathogenesis in multiple in vitro and in vivo models systems, suggesting that the pathway represents an attractive therapeutic target.  Recent efforts have focused on innovative strategies to antagonize Wnt signaling at various levels of the pathway – from attenuating the extracellular signaling through the Wnt receptors to modulating the catenin destruction complex to blocking catenin-mediated transcription. Many of these approaches have been largely successful in preclinical validation studies and have been met with considerable enthusiasm to move forward into clinical trials. In this book, we highlight the recent advances in our understanding of the complexity of the Wnt pathway, particularly its intricate regulation and cross-talk with other key signal transduction pathways in normal and tumor cells. As a way to comprehend the role of Wnt pathway activation in tumor initiation and progression, we discuss the importance of Wnt signaling in embryonic and tissue development and stem cell maintenance and self-renewal. The evidence for aberrant Wnt pathway activation in human solid and hematopoietic cancers, as well as a few of the genetic mouse models that mimic the Wnt pathway deregulation observed in some of these tumor types, is reviewed. Lastly, we summarize the current status of the development of Wnt pathway inhibitors, their efficacy in preclinical models and their potential as therapeutic agents for cancer. It is an exciting time in the Wnt signaling field – one that represents a key crossroad between dissecting the molecular details of the pathway and translating that work into promising targeted tumor therapies – that is likely to profoundly impact this research area for years to come.

Keywords

Cancer Research Targeting Wnt Wnt Wnt Pathway

Editors and affiliations

  • Kathleen H. Goss
    • 1
  • Michael Kahn
    • 2
  1. 1.Medical Center, Dept. SurgeryUniversity of ChicagoChicagoUSA
  2. 2.Eli & Edythe Broad Center for, Regenerative Medicine &University of Southern CaliforniaLos AngelesUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4419-8023-6
  • Copyright Information Springer Science+Business Media, LLC 2011
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-1-4419-8022-9
  • Online ISBN 978-1-4419-8023-6
  • Buy this book on publisher's site